Risk of Autoimmune Hepatitis Among Patients with Inflammatory Bowel Disease Treated with Infliximab: A Retrospective Cohort Study Using a National Database - PubMed
5 hours ago
- #Inflammatory Bowel Disease
- #Autoimmune Hepatitis
- #Drug Safety
- Infliximab is associated with a higher risk of autoimmune hepatitis compared to adalimumab in patients with inflammatory bowel disease.
- The study used a retrospective cohort design with 15,298 matched patients in each treatment group.
- Autoimmune hepatitis occurred in 0.216% of infliximab users versus 0.085% of adalimumab users, with a risk ratio of 2.53.